New AI tool accurately predicts both overall survival and disease-free survival after colorectal cancer diagnosis.
The model uses visual markers on pathology images to glean insights into a tumor’s genomic profile and predicts tumor behavior, disease progression, treatment response.
The new model could help augment clinical decision-making.
Because the AI tool relies on images alone, it could be particularly valuable for hospitals lacking the technology or expertise to perform sophisticated genomic profiling of tumor tissues.
Model Provides Actionable Insights for Physicians to Augment Clinical Decisions miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
E-Mail
BOSTON - Many patients with cancer receive immune checkpoint inhibitors that strengthen their immune response against tumor cells. While the medications can be life-saving, they can also cause potentially life-threatening side effects in internal organs. This double-edged sword makes it challenging for clinicians to decide who should be considered candidates for treatment. A new analysis led by researchers at Massachusetts General Hospital (MGH) indicates which patients are at elevated risk of side effects severe enough to require hospitalization. The findings are published in the Understanding the risk factors for predicting high-grade toxicities will help in appropriately selecting patients most likely to tolerate immune checkpoint inhibitor therapy, says co-senior author Yevgeniy R. Semenov, MD, an investigator in the Department of Dermatology at MGH. It will also help to identify higher risk patients who should be carefully monitored if they initiate this therapy.
E-Mail
BOSTON - Immune checkpoint inhibitors, which boost the immune system s response against tumor cells, have transformed treatment for many advanced cancers, but short-term clinical trials and small observational studies have linked the medications with various side effects, most commonly involving the skin. A more comprehensive, population-level analysis now provides a thorough look at the extent of these side effects and provides insights on which patients may be more likely to experience them. The research was led by investigators at Massachusetts General Hospital (MGH) and is published in the Immunotherapies, which include immune checkpoint inhibitors, are an increasingly common treatment modality for advanced cancers, with more than 200,000 patients being started on these therapies annually, says co-senior author Yevgeniy R. Semenov, MD, an investigator in the Department of Dermatology at MGH. As the use of immune checkpoint inhibitors increases, so will the incidenc